Circle Pharma, Inc.

13 articles about Circle Pharma, Inc.

• Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor Presented at 2023 AACR-NCI-EORTC International Conference

  10/23/2023

  Circle Pharma, in collaboration with the laboratory of Violeta Serra, Ph.D., at Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain, recently unveiled preclinical data demonstrating the efficacy of Circle’s oral Cyclin A/B inhibitor macrocycles in patient-derived breast cancer tumor models.

• Circle Pharma strengthens its executive leadership team with two senior appointments in Clinical Development

  7/26/2023

  Circle Pharma announced today the appointments of Michael Cox, PharmD., MHSc, BCOP as senior vice president, head of Early Development, and Edward Garmey, M.D., as its new consulting chief medical officer.

• Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B

  7/19/2023

  Circle Pharma announced today the selection of CID-078 for its first clinical development program. CID-078 is the first-and-only-in-class dual inhibitor of Cyclins A and B.

• Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting

  4/20/2023

  Circle Pharma announced that two poster presentations at the American Association for Cancer Research Annual Meeting held April 14-19, in Orlando, Florida, highlight promising pre-clinical data of its first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors targeting intractable cancers.

• Circle Pharma Appoints Paul Park, MBA, as its Chief Business Officer

  7/26/2022

  Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Paul Park, MBA, as its Chief Business Officer.

• Circle Pharma Announces Presentation at the American Association for Cancer Research 2022 Annual Meeting

  4/11/2022

  Circle Pharma will present a poster at the American Association for Cancer Research (AACR) Annual Meeting being held April 8-13, in New Orleans, Louisiana.

• Circle Pharma Appoints Constantine Kreatsoulas, PhD as its Vice President, Research Informatics and Computational Chemistry

  2/1/2021

  Constantine Kreatsoulas, PhD has joined Circle Pharma as its Vice President of Research Informatics and Computational Chemistry. Dr. Kreatsoulas joins Circle from GlaxoSmithKline (GSK) where he was the Head of US Molecular Design and Interim Head of Computational Toxicology.

• Circle Pharma Appoints Alan Ashworth, PhD, FRS and Bruce Stillman, PhD, FRS to Its SAB

  10/21/2020

  Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, has appointed Prof. Alan Ashworth, PhD, FRS and Bruce Stillman, PhD, FRS to its Scientific Advisory Board.

• Circle Pharma Appoints Rajinder Singh, PhD as its Chief Science Officer

  7/20/2020

  Circle Pharma, Inc. has appointed Rajinder Singh, PhD as its Chief Science Officer. Dr. Singh will oversee Circle’s scientific work to develop macrocycle therapeutics against intractable cancer targets. Dr. Singh has 25 years of experience in drug discovery and development, spanning small molecules, peptides and peptoids. He most recently served as Senior Vice President of Research and Pharmaceutics at C

• Circle Pharma Appoints William G. Kaelin Jr. MD as Chair of Its Scientific Advisory Board

  5/27/2020

  Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, has appointed William G. Kaelin Jr. MD as Chair of its Scientific Advisory Board and Science Advisor to its Board of Directors. Dr. Kaelin is a Howard Hughes Medical Institute Investigator and a professor of medicine at Dana Farber Cancer Institute and Harvard Medical School. He was awarded the

• CORRECTING and REPLACING Circle Pharma Raises $45 Million in Series B Financing

  3/17/2020

  Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, announced that it has raised $45 million in a Series B financing.

• Circle Pharma Raises $45 Million in Series B Financing

  3/17/2020

  Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, today announced that it has raised $45 million in a Series B financing.

• Circle Pharma Congratulates Dr. William G. Kaelin, Jr., MD on Award of Nobel Prize

  10/8/2019

  The prize was awarded for their work on discovering how cells detect and respond to changes in oxygen availability, a process that is key to the survival of many cancers.